Plaque Psoriasis

A higher proportion of risankizumab users achieved improved measures for symptoms, quality of life, and mental health versus comparators.

Ustekinumab should be prescribed cautiously to those at high cardiovascular risk.

More studies are needed on the effectiveness and safety of plaque psoriasis therapies for older patients.

The expansion makes history for the injection biologic.

Investigators found 30 mg of apremilast results in a significant reduction in plaque psoriasis patients.

An assessment of survey data show patients with severe depressive or psychological symptoms are more likely to be dissatisfied with their dermatologist.

A dermatologist discusses how to care for patients with psoriasis during the COVID-19 pandemic.

The IL-17A-targeting biologic has now been indicated for pediatric plaque psoriasis—marking its fourth indication for patients with chronic diseases.

New phase 3 IMMhance findings show durable, sustained effect of the IL-23 inhibitor on a 12-week dose regimen.